PHARMA MAR, S.A. «...678910...» Page 9 out of 23 28/02/2023 17:12 PHARMA MAR, S.A. Annual corporate governance report La sociedad remite el Informe Anual de Gobierno Corporativo del ejercicio 2022 Register number: 20970 28/02/2023 16:10 PHARMA MAR, S.A. Annual financial reports and audit reports La sociedad remite el Informe Financiero Anual del ejercicio 2022 Register number: 20956 28/02/2023 15:38 PHARMA MAR, S.A. Other relevant information - On business and financial situation The Company reports draw up of the Annual Financial Statements 2022, a proposal for a dividend, and a conference call with analysts and investors. Register number: 20955 28/02/2023 15:24 PHARMA MAR, S.A. On business and financial situation The Company sends press release regarding year 2022 results together with financial report. Register number: 20951 28/02/2023 15:21 PHARMA MAR, S.A. Half-yearly financial reports and audit reports/limited audit review La sociedad remite información financiera del segundo semestre de 2022 Register number: 20949 31/01/2023 08:27 PHARMA MAR, S.A. On business and financial situation The Company announces the approval of Zepzelca® (lurbinectedin) for the treatment of metastatic Small Cell Lung Cancer in Israel Register number: 20212 26/01/2023 13:59 PHARMA MAR, S.A. Board of Directors Regulations La sociedad remite el reglamento del Consejo de Administración Register number: 20160 24/01/2023 08:28 PHARMA MAR, S.A. On business and financial situation The Company announces the approval of Zepzelca® (lurbinectedin) for the treatment of metastatic Small Cell Lung Cancer in Mexico Register number: 20106 09/01/2023 11:16 PHARMA MAR, S.A. Liquidity and counterparty agreements The Company reports details of the operations of the Liquidity Agreement between 01/10/2022 and 31/12/2022 Register number: 19929 30/12/2022 08:27 PHARMA MAR, S.A. On business and financial situation Press release on the entry into clinical trials of a new Pharma Mar anti-tumour compound Register number: 19818 Page 9 out of 23 «...678910...»
